Though multiple markers related to immune cell activation decreased with abatacept therapy, CXCL13 and IgM RF decreased only in responders and could be potentially used as pharmacodynamic markers for abatacept in RA treatment. This evidence concerns the gene CD40LG and rheumatoid arthritis.